Arginase as a new concern in blood transfusion

Blood Transfusion

Volumn 12, Issue SUPPL.1, 2014, Pages

  Mollinedo, Faustino ^a   Palomero Rodríguez, Miguel Angel ^b   Sánchez Conde, Pilar ^b   Garcia Navas, Rósula ^a   Laporta Báez, Yolanda ^c   De Vicente Sánchez, Jesús ^c   Suarez Gonzalo, Luis ^c  

^a Centro de Investigacion del Cancer   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGININE; BLOOD PRESERVATION; BLOOD TRANSFUSION; ERYTHROCYTE TRANSFUSION; HEMOLYSIS; HUMANS; IMMUNOSUPPRESSION; NEUTROPHILS; TIME FACTORS;

EID: 84883753176     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0237-12     Document Type: Letter

References (5)

1. Atzil S, Arad M, Glasner A, et al. Blood transfusion promotes cancer progression: a critical role for aged erythrocytes. Anesthesiology 2008; 109: 989-97.
2. Saager L, Turan A, Dalton JE, et al. Erythrocyte storage duration is not associated with increased mortality in noncardiac surgical patients: a retrospective analysis of 6,994 patients. Anesthesiology 2013; 118: 51-8.
3. Berra L, Coppadoro A, Yu B, et al. Transfusion of stored autologous blood does not alter reactive hyperemia index in healthy volunteers. Anesthesiology 2012; 117: 56-63.
4. Munder M, Mollinedo F, Calafat J, et al. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood 2005; 105: 2549-56.
5. Romero PA, Stone E, Lamb C, et al. SCHEMA designed variants of human arginase I & II reveal sequence elements important to stability and catalysis. ACS Synth Biol 2012; 1: 221-8.